Resources and Tools

The following resources and tools provided by CSL Behring are designed to help you and your patients better understand von Willebrand disease (VWD) and its treatment.

Resources

Self Infusion
Help your patients learn to self-infuse Humate-P at home. Watch the video.

Interactive Learning Program for Pharmacists
This program contains flash animation, audio narration, and learning questions to help Pharmacists better understand VWD and how they can play a more active role in its treatment with Humate-P^®.

Request More Information
Register for our quarterly e-mail updates to stay informed about the latest research on VWD.

Educational Materials
Order educational brochures and guides to help you identify and treat patients with VWD, and patient brochures and guides to help your VWD patients successfully handle their condition.

Journal Reprints
Order reprints of journal articles detailing clinical research on VWD, its causes, its effects, and its treatment.

Educational Program Links
Learn more about our wide array of educational seminars and continuing medical education programs.

AllAboutBleeding-US.com
Access a Web site dedicated to increasing awareness about Bleeding Disorders, von Willebrand Disease (VWD), Hemophilia and other rare bleeding disorders.

Reimbursement Resource Center
CSL Behring provides a range of reimbursement services, including individual claims processing reviews, assistance in appeals, insurance investigations into product coverage, and prior approvals for therapies authorization. To speak with a representative, call the Reimbursement Answerline at 1-800-676-4266 Monday through Friday from 8 a.m. to 5 p.m. ET.

P&T Commmunity
For more managed care and formulary information about Humate-P visit formkit at :

Humate P:http://www.ptcommunity.com/Formkits/brandHome.cfm?fkID=129&action=track

Note that you must be a confirmed P&T committee member to have access. If you’d like to check your status, request your log in codes, or register for the site, please send an e-mail to Tony Berberabe at tberberabe@medimedia.com

Tools

Dosage Calculator
Our unique Humate-P^® Dosage Calculator makes individual dosing fast, easy, and convenient.

Customizable Patient Materials
You can select from a variety of patient education materials, customized with your contact information.

VWF Densitometric Analysis
The densitometric analysis compares various VWF/FVIII concentrates and normal human plasma.

Important Safety Information

Humate-P is indicated for treatment and prevention of bleeding in adult patients with hemophilia A (classical hemophilia). Humate-P is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate. Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes.

Humate-P is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations.

Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B, and AB blood groups who are receiving large or frequent doses. Also monitor VWF:RCo and FVIII levels in VWD patients, especially those undergoing surgery.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement. Caution should be exercised and antithrombotic measures considered, particularly in patients with known risk factors for thrombosis.

Humate-P is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In patients receiving Humate-P in clinical studies for treatment of VWD, the most commonly reported adverse reactions observed by >5% of subjects are allergic-anaphylactic reactions, including urticaria (hives), chest tightness, rash, pruritus (itching), and edema (swelling). For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding, and epistaxis (nosebleed).

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.